who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Eric Rubenstein of New Climate Ventures, Susan Davenport of Greater Houston Partnership, and Zimri T. Hinshaw of Bucha Bio. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from venture capital to sustainability — recently making headlines in Houston innovation.


Eric Rubenstein, founding managing partner of New Climate Ventures

Eric Rubenstein of New Climate Ventures joins the Houston Innovators Podcast to discuss the future of Houston as a clean energy hub. Photo courtesy of NCV

Houston has a big role to play in the energy transition, says Eric Rubenstein, a climatetech investor, on last week's episode of the Houston Innovators Podcast.

"Houston's role (within the energy transition) is multifaceted," he explains. "We have a talent pool here that fits pretty well in climate tech, alternative materials, and other spaces. ...We have a customer base here that is going to adopt these new technologies."

Rubenstein founded New Climate Ventures to fund startups within the sustainability and climate tech space — which includes technologies that address circular economy, sustainably made materials, clean energy, and more. Click here to read more and stream the episode.

Susan Davenport, chief economic development officer for the Greater Houston Partnership

The Greater Houston Partnership's Susan Davenport shares details on Houston House at SXSW. Photo via houston.org

Last year, the Greater Houston Partnership created virtual content to shine a spotlight on Houston tech and innovation at SXSW. This year, the GHP is taking that same initiative in-person and in Austin. Susan Davenport, chief economic development officer at GHP, shared in a Q&A what people can expect fro Houston House at SXSW.

"Anyone who is interested in technology, commercial aerospace, life sciences, and how DEI traverses with these industries will find value in our rockstar lineup of industry leaders, investors, and startup founders," she says. "We hope to see young professionals, entrepreneurs, investors, and executives."

The activation runs Sunday, March 13, and Monday, March 14. Click here to read more.

Zimri T. Hinshaw, CEO of Bucha Bio

Bucha Bio has arrived to make an impact on the city of Houston. Image via LinkedIn

A sustainable fashion company has relocated to Houston. Bucha Bio, founded in 2019, creates in textiles and composite materials made from bacterial nanocellulose, a much more sustainable materials production, that can be used instead of animal leather, polyurethane, latex, vinyl, epoxy, and more. The company announced in a press release today that it's moving from New York City and opening a next-gen materials headquarters at the East End Maker Hub. Bucha Bio has also been accepted as a member company at Greentown Labs.

According to the release, over 20 locations were considered, and Houston stood out for its hiring potential, local universities, Texas's business-friendly regulation, and more.

“We’ve signed on senior scientists and their experiences from the oil and plastic industry are perfectly suited to biomaterials,” says Zimri T. Hinshaw, CEO of Bucha Bio, in the release. Click here to read more.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News